Michael V. Seiden

14.1k total citations · 3 hit papers
172 papers, 8.5k citations indexed

About

Michael V. Seiden is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Michael V. Seiden has authored 172 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 65 papers in Reproductive Medicine and 45 papers in Molecular Biology. Recurrent topics in Michael V. Seiden's work include Ovarian cancer diagnosis and treatment (65 papers), Cancer Genomics and Diagnostics (20 papers) and Intraperitoneal and Appendiceal Malignancies (18 papers). Michael V. Seiden is often cited by papers focused on Ovarian cancer diagnosis and treatment (65 papers), Cancer Genomics and Diagnostics (20 papers) and Intraperitoneal and Appendiceal Malignancies (18 papers). Michael V. Seiden collaborates with scholars based in United States, United Kingdom and Canada. Michael V. Seiden's co-authors include Zhenfeng Duan, Richard T. Penson, Diana E. Lamendola, Mansoor M. Amiji, Rosemary Foster, Ursula A. Matulonis, Rukh Yusuf, Katherine A. Brakora, Lilian E. van Vlerken and Frank G. Haluska and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael V. Seiden

170 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 778 citations Michael V. Seiden et al. profile →
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

2021 520 citations Eric A. Klein, Kathryn N. Kurtzman et al. profile →
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 488 citations Michael V. Seiden et al. profile →

Peers

Countries citing papers authored by Michael V. Seiden

Since Specialization

Citations

This map shows the geographic impact of Michael V. Seiden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael V. Seiden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael V. Seiden more than expected).

Fields of papers citing papers by Michael V. Seiden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael V. Seiden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael V. Seiden. The network helps show where Michael V. Seiden may publish in the future.

Co-authorship network of co-authors of Michael V. Seiden

This figure shows the co-authorship network connecting the top 25 collaborators of Michael V. Seiden. A scholar is included among the top collaborators of Michael V. Seiden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael V. Seiden. Michael V. Seiden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health State Utilities Associated with False-Positive Cancer Screening Results 2024 ·PharmacoEconomics - Open ·Louis S. Matza, (unknown), Eric T. Fung, Sam M. Janes, Michael V. Seiden, Allan Hackshaw, Lincoln Nadauld, (unknown), Karen Chung	2
2	POSC356 Pilot Study for Assessment of Health State Utilities Associated with False-Positive Cancer Screening Results 2022 ·Value in Health ·Louis S. Matza, (unknown), Eric T. Fung, Sam M. Janes, Michael V. Seiden, Allan Hackshaw, Lincoln Nadauld, (unknown)	1
3	Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests 2022 ·Patient ·Heather L. Gelhorn, Melissa Ross, M. Feldman, Eric T. Fung, Michael V. Seiden, Nicolas Krucien, Karen Chung	23
4	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA 2021 ·Clinical Cancer Research ·Xiaoji Chen, Dong Zhao, Earl Hubbell, Kathryn N. Kurtzman, Geoffrey R. Oxnard, Oliver Venn, Collin Melton, Christina A. Clarke, Rita Shaknovich, (unknown), (unknown), Michael V. Seiden, Eric A. Klein, Eric T. Fung, Minetta C. Liu	79
5	Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin 2019 ·Gynecologic Oncology ·Carolyn Krasner, Cesar M. Castro, Richard T. Penson, Maria Roche, Ursula A. Matulonis, Mark A. Morgan, Charles W. Drescher, Deborah K. Armstrong, (unknown), Hee Jun Lee, Jeffrey G. Supko, Michael V. Seiden, Michael J. Birrer, Don S. Dizon	5
6	Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma 2012 ·Clinical Cancer Research ·Jean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma, Ben Davidson, Mari Bunkholt Elstrand, Ram Ganapathi, Aparna A. Kamat, Anil K. Sood, Suresh V. Ambudkar, Michael V. Seiden, Bo R. Rueda, Michael M. Gottesman	40
7	Augmentation of Therapeutic Efficacy in Drug-Resistant Tumor Models Using Ceramide Coadministration in Temporal-Controlled Polymer-Blend Nanoparticle Delivery Systems 2010 ·The AAPS Journal ·Lilian E. van Vlerken, Zhenfeng Duan, Steven R. Little, Michael V. Seiden, Mansoor M. Amiji	43
8	Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer 2010 ·Cancer ·Gisele Sarosy, Mahrukh M. Hussain, Michael V. Seiden, Arlan F. Fuller, Najmosama Nikrui, Annekathryn Goodman, Lori M. Minasian, Eddie Reed, Seth M. Steinberg, Elise C. Kohn	23
9	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells 2008 ·Cancer Chemotherapy and Pharmacology ·Zhenfeng Duan, (unknown), Meagan B. Ryan, Francis J. Hornicek, Henry J. Mankin, Michael V. Seiden	65
10	Mechanisms of Cables 1 gene inactivation in human ovarian cancer development 2008 ·Cancer Biology & Therapy ·Hideo Sakamoto, Anne M. Friel, Antony W. Wood, Lankai Guo, (unknown), Michael V. Seiden, Daniel C. Chung, Maureen P. Lynch, Takehiro Serikawa, Elizabeth Munro, Esther Oliva, Sandra Oršulić, Sandra D. Kirley, Rosemary Foster, Lawrence Zukerberg, Bo R. Rueda	16
11	GBP1 overexpression is associated with a paclitaxel resistance phenotype 2005 ·Cancer Chemotherapy and Pharmacology ·Zhenfeng Duan, Rosemary Foster, Katherine A. Brakora, Rushdia Z. Yusuf, Michael V. Seiden	50
12	A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer 2005 ·Gynecologic Oncology ·Michael V. Seiden, Alan N. Gordon, Diane C. Bodurka, Ursula A. Matulonis, Richard T. Penson, Eddie Reed, (unknown), (unknown), Michael Cullen, William P. McGuire	23
13	Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy 2004 ·Journal of Clinical Oncology ·Rocio García‐Carbonero, (unknown), Judith Manola, Michael V. Seiden, David C. Harmon, David P. Ryan, Mikayla Quigley, Priscilla Merriam, Jennifer Canniff, Geraldine Goss, U. Matulonis, Robert G. Maki, María Teresa Rugeles López, Thomas A. Puchalski, (unknown), Javier Gómez, C. Guzmán, José Jimeno, George D. Demetri	250
14	Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors 2003 ·Gynecologic Oncology ·(unknown), Ursula A. Matulonis, Richard T. Penson, Hang Lee, Ross S. Berkowitz, Linda Duska, Arlan F. Fuller, (unknown), Thomas A. Puchalski, Jeffrey G. Supko, Michael V. Seiden	21
15	Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation 2003 ·Current Cancer Drug Targets ·Rukh Yusuf, (unknown), Diana E. Lamendola, Richard T. Penson, Michael V. Seiden	293
16	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity 2002 ·Cancer Chemotherapy and Pharmacology ·Thomas A. Puchalski, David P. Ryan, Rocio García‐Carbonero, George D. Demetri, (unknown), David C. Harmon, Michael V. Seiden, Robert G. Maki, Luis López Lázaro, José Jimeno, Cecilia Guzmán, Jeffrey G. Supko	55
17	The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer 2001 ·Gynecologic Oncology ·Susana M. Campos, Richard T. Penson, (unknown), Ross S. Berkowitz, Arlan F. Fuller, Annekathryn Goodman, Ursula A. Matulonis, Alona Muzikansky, Michael V. Seiden	91
18	Successful Pregnancy after High-Dose Cyclophosphamide, Carboplatinum, and Taxol with Peripheral Blood Stem Cell Transplant in a Young Woman with Ovarian Carcinoma 2001 ·Gynecologic Oncology ·Michael V. Seiden, Thomas R. Spitzer, SL McAfee, Arlan F. Fuller	5
19	Efficacy and Hematologic Toxicity of Salvage Chemotherapy Following Stem Cell-Supported High-Dose Chemotherapy in Women with Recurrent Ovarian Cancer 2000 ·Gynecologic Oncology ·Sarah Cook, Richard T. Penson, Linda Duska, Najmosama Nikrui, (unknown), (unknown), Michael V. Seiden	3
20	Chemical synthesis of idiotopes. Evidence that antisera to the same JH1 peptide detect multiple binding site-associated idiotopes. 1984 ·The Journal of Experimental Medicine ·Michael V. Seiden, B L Clevinger, (unknown), (unknown), Richard A. Lerner, Joseph M. Davie	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact